Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
ECDC is organising a physical workshop between 16 and 18 April 2024 with national experts to develop a public health guidance to support the assessment of the risk of locally-acquired Aedes-borne viral diseases in the EU/EEA.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Information on autochthonous vectorial transmission of dengue in mainland EU/EEA, including location, period, number of cases, virus serotype and mode of transmission.